Ecuador Post-Registration Control: Type 1 and Type 2 Inspections under Articles 64 and 65

1. Key takeaways

Articles 64 and 65 create a two-tier post-registration control (control posregistro) system. Type 1 is a visual verification of the label, the instructions for use, the useful life and the storage conditions. Type 2 is the drawing of a representative sample and its submission to the ARCSA reference laboratory or to a laboratory designated by ARCSA for quality control analysis. Controls are initiated under the annual plan, which follows a risk management approach, or in response to a complaint, a health alert or a request from the national health authority.

The distinction that matters commercially is where the check happens. A Type 1 control is an inspection of documents and physical presentation at the establishment; a Type 2 control removes product from the market and produces an analytical result that is compared with what was approved.

Both tiers share one benchmark: the information recorded in the registration certificate. The regulation does not test the device against an abstract standard. It tests the device on the market against the file the holder itself submitted, which makes dossier discipline a post-market control issue rather than a pre-market formality.

2. Legal basis

Structure of Article 65:

• First paragraph: post-registration control and establishment inspections are carried out under the annual plan drawn up by ARCSA, on the basis of a risk management approach, and are triggered by complaints, health alerts or a request from the national health authority;
• Second paragraph: post-registration control comprises two tiers, Type 1 or Type 2;
• Third paragraph (Type 1): visual verification of the minimum content requirements for labels and instructions for use, of the useful life and of the storage conditions, against the information approved in the registration certificate;
• Fourth paragraph (Type 2): representative samples are drawn and submitted to the ARCSA reference laboratory or to a laboratory designated by ARCSA for quality control analysis; through that analysis ARCSA verifies whether the specifications of the product match the information approved in the registration certificate.

3. Expert insights

Insight one: the four objects of Type 1 map onto four items in the dossier. Label, instructions for use, useful life and storage conditions correspond to Article 49 (label), Article 52 (instructions for use), Article 24, item 1.9 A (stability and shelf life) and Article 49, items (e) and (j) (storage conditions and storage temperature). Type 1 is therefore an exercise in checking that the physical product on the market is consistent with the registration file.

Insight two: the Type 2 benchmark is consistency with the approved information. The text states that ARCSA verifies whether the specifications of the product match the information approved in the registration certificate. The technical specifications submitted at filing become the yardstick for later sampling, so an over-optimistic specification will not be corrected by the market: it will be failed by the laboratory.

Insight three: there are four triggers, and three of them are passive. The annual plan is the active route; complaints, health alerts and authority requests are reactive. Competitor complaints and vigilance reports from healthcare institutions are the main external sources of an unplanned inspection, and neither is within the holder’s control.

Insight four: Article 66 distinguishes who bears the sample. Samples may be drawn during an inspection and returned by the holder to the place where they were drawn, with an exception where the inspection takes place at the holder’s own establishment. The sampling cost therefore sits with the holder, and the return logistics need an owner before an inspection happens.

Insight five: Article 64 reaches the whole chain, not only the holder. The inspection scope covers establishments that manufacture, store, distribute, commercialise, transport, dispense and sell devices, as well as the technical review of those products. A compliant holder with a non-compliant distributor remains exposed at the point where the product is found.

Insight six: Article 67 is the preparation clause for inspections. The holder must keep the technical file supporting every registration requirement of the regulation, and ARCSA may call for it at any time it considers necessary. A missing file is itself a breach, independently of whether the device performs as claimed.

4. Practical recommendations

1. Build a consistency check between the physical product and the registration file, and compare the printed label with the approved content at fixed intervals.
2. Leave a realistic tolerance margin when stating technical specifications, so that a Type 2 analysis does not fail on an ambitious claim.
3. Keep the technical file locally available under Article 67, with a named custodian and a retrieval time measured in hours.
4. Feed complaint and vigilance information into an internal early-warning review, to anticipate the passive triggers.
5. Reserve a budget for Type 2 sampling and testing, and confirm the sample return route with the holder in advance.

5. Verification checklist

• □ A consistency check between the physical product and the registration file has been established
• □ A reasonable tolerance margin has been left in the technical specifications filed
• □ The technical file is kept locally under Article 67
• □ Complaint and vigilance information is included in the internal early-warning mechanism
• □ A budget for Type 2 sampling and testing has been reserved
• □ The sample return process has been confirmed with the holder

Regulatory information verified as of October 29, 2026

GRZAN core service lines

1. Global registration access: EU CE (MDR/IVDR), US FDA (510(k)/De Novo/PMA), UK UKCA, Australia TGA, Canada Health Canada, Brazil ANVISA and Russia RZN, together with pre-market registration pathway planning and submission execution across Latin America, Southeast Asia and the Middle East.
2. Authorized representative services: EU EC REP, UK RP, Swiss CH REP, Australian sponsor and US Agent holding and representation services, with support for neutral license-holder structures.
3. Quality system compliance: ISO 13485 establishment and maintenance, MDSAP audit preparation, GMP conformity coaching, and technical documentation (TD) drafting and remediation.
4. Clinical and evaluation support: clinical evaluation plans (CEP) and reports (CER), equivalence argumentation, PMCF planning and execution, and IVD performance evaluation.
5. Post-market compliance: vigilance and adverse event reporting, FSCA and recall execution, registration change and renewal management, and maintenance of national regulatory databases.

Why manufacturers choose GRZAN

• Local regulatory teams: target-market work is performed by locally licensed regulatory professionals, and submission dossiers are written directly in the local official language without secondary translation.
• Neutral license-holder structures: GRZAN offers holding arrangements that are not tied to any distribution channel, preventing registration certificates from being locked in by channel partners.
• Regional leverage: one technical dossier can be reused across Andean Community and Mercosur member states, spreading regional compliance costs.
• Full lifecycle support: from classification determination and pathway design through dossier preparation, license holding, customs clearance, post-market vigilance and renewal.

Contact

• GRZAN provides registration support in Ecuador for manufacturers, importers and authorized representatives.
• Email: info@grzanglobal.com
• Service inquiries: Ecuador and Andean market registration plans, license-holder structure design, official fee and timeline estimation